AdaptVac’s technology allows the rapid development of a COVID-19 vaccine to begin clinical trials in late 2020. Virus-Like Particles (VLPs) represent a significant advance in the development of subunit vaccines, combining high safety and efficacy. Their particulate nature and dense repetitive subunit organization makes them ideal scaffolds for display of vaccine antigens.

“We strongly believe that our capsid Virus-Like Particle display technology will be a key player in global emergencies, such as the COVID-19 epidemic, and have carefully selected AGC Biologics as our trusted partner in the development and production of this vaccine. We are grateful to AGC for providing additional COVID-19 vaccine development support, ensuring vaccine production can happen in the fastest possible timeline,” says Wian de Jongh, AdaptVac’s CEO.
“The urgency level to develop and produce a vaccine to combat COVID-19 could not be higher,” says AGC Biologics CEO Patricio Massera. “We are honored to partner with AdaptVac and be part of the consortium team that is working to develop an efficient vaccine. We value collaborative partnerships and believe working together to fight this pandemic is crucial.”

AdaptVac Learn more at www.adaptvac.com and www.expres2ionbio.com.

AGC Biologics Learn more at www.agcbio.com.